SCHEMBL5637034

SCHEMBL5637034

O=[C]N[C@H]1CCCCN(C(=O)Nc2ccc(F)cc2)C1=O

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.49
▸ ALDH1A1 P00352 2/20 0.48
▸ THRB P10828 2/20 0.45
▸ ALOX12 P18054 1/20 0.45
▸ RAB9A P51151 4/20 0.44
▸ NPC1 O15118 3/20 0.44
▸ MAPT P10636 1/20 0.44
▸ NAMPT P43490 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ EPHX1 P07099 1/20 0.41
▸ FPR2 P25090 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5638857 0.88 NPC1 (0.49) KMT2AALDH1A1RAB9ANPC1MAPT
SCHEMBL5640329 0.88 SMN1; SMN2 (0.46) KMT2AALDH1A1RAB9ANPC1MAPT
SCHEMBL5638348 0.86 NPC1 (0.49) KMT2AALDH1A1RAB9ANPC1MAPT
SCHEMBL5637096 0.84 ALDH1A1 (0.52) KMT2AALDH1A1THRBALOX12RAB9A
SCHEMBL5637037 0.83 KMT2A (0.49) KMT2AALDH1A1THRBALOX12RAB9A
SCHEMBL5638120 0.82 ALDH1A1 (0.38) KMT2AALDH1A1RAB9AMAPTSMN1; SMN2
SCHEMBL5638422 0.81 KMT2A (0.43) KMT2AALDH1A1RAB9ANPC1MAPT
SCHEMBL5638974 0.80 KMT2A (0.54) KMT2AALDH1A1THRBALOX12RAB9A
SCHEMBL5637705 0.77 POLB (0.35) ALDH1A1
SCHEMBL5637024 0.77 POLB (0.35) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220856-B2 Substituted quinoline CCR5 receptor antagonists SCHERING AKTIENGESELLSCHAFT (DE) 2007-05-22 — — US disclosed
US-20040072818-A1 Substituted quinoline CCR5 receptor antagonists SCHERING AKTIENGESELLSCHAFT (DE) 2004-04-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040072818-A1 Substituted quinoline CCR5 receptor antagonists CCR5, CXCR3, CCR2 KMT2A 3541/4885ALDH1A1 1286/4885THRB 814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback